Industry & Policy Reporter
Sara reports on AI policy, ethics and enterprise adoption across sectors.
2
articles
The European Union's AI Act has entered its first enforcement phase, requiring companies deploying high-risk AI systems to register with national authorities and submit conformity assessments.
Drug candidates identified using generative AI models have progressed to Phase II clinical trials, marking a significant milestone in AI-accelerated pharmaceutical development.